Hutch News
In Uganda: Treating twin threats of HIV and cancer
Dr. Sue Desmond-Hellmann of the Bill & Melinda Gates Foundation visits Hutch researchers in Kampala
New HIV vaccine trial to launch in U.S., Latin America and Europe
‘Mosaico’ will enroll 3,800 transgender people and men who have sex with men
Improving HIV clinical trials with mobile technology
From the HIV Vaccine Trials Network, Vaccine and Infectious Disease Division
Could gold be the key to making gene therapy for HIV and other blood disorders more accessible?
A proof-of-principle study published in Nature Materials shows that gold nanoparticles loaded with CRISPR and other gene-editing tools safely and effectively edited blood stem cells. (Photos, diagram available for media use.)
Special delivery: Gold nanoparticles ship CRISPR cargo
Fred Hutch scientists used their new golden courier to edit genes tied to HIV, genetic blood disorders
Machine learning predicts HIV pseudovirus antibody neutralization
From the Gilbert group, Vaccine and Infectious Disease Division
Could an infant’s blood sample help model a better HIV vaccine?
Tracing the evolution of a baby’s special HIV-blocking protein
Increased racial and ethnic minority participation in HIV vaccine trials
From the HIV Vaccine Trials Network, Vaccine and Infectious Disease Division
Fred Hutch’s Dr. Adam Dingens a 2019 Weintraub Award recipient
He is among 13 graduate students selected for this prestigious award in biological sciences
.JPG)
London transplant doctors report a second person likely cured of HIV
12 years after Timothy Ray Brown was cured, we have another
Scientists strategize to stop HIV infections, work toward cure
A hot topic for a big scientific conference convening in Seattle
Sabes study fuels comprehensive HIV research
From the Duerr lab, Vaccine and Infectious Disease Division, and collaborators
Cutting-edge approach maps HIV's escape routes
Atlas of immune-evading HIV mutations could inform design of new treatments, vaccines
Modified HIV immunogens engage neutralizing antibody precursors
From the Stamatatos lab, Vaccine and Infectious Disease Division
Models identify cellular proliferation as driver of HIV persistence
From the Schiffer group, Vaccine and Infectious Disease Division
Despite early rise, longterm ART decreases HSV shedding
From the Corey lab, Vaccine and Infectious Disease Division
Exploring why people with HIV have a higher lung cancer risk
120 volunteers to enroll in Seattle-area study of cancer-related gene mutations
'Cautiously optimistic about HIV vaccines'
A conversation in advance of World AIDS Day with pioneering HIV researcher Dr. Larry Corey
Study aims to cure blood cancers with transplants that could block HIV, too
10 HIV-positive cancer patients to receive donated cord blood with rare resistance gene
One step closer to the Berlin Patient and an HIV cure
Kiem Lab, Clinical Research Division and Vaccine and Infections Disease Division
Predicting a moving target’s next move
From the Bloom Lab, Basic Sciences Division
Gene editing holds promise for shrinking HIV ‘reservoir’
Study mimicking Timothy Ray Brown’s HIV-resistant mutation led to fewer latently infected cells — a key step toward driving the virus into remission without the need for antivirals
The interplay between antibodies and T cells in HIV risk
From the HVTN and Vaccine and Infectious Disease Division
25 powerful years of HIV research
Longstanding Mombasa Cohort helps answer questions about HIV risk and transmission